This orchestrated process involves the release of inflammatory factors, such as IL-18 and IL-1β, which attract dendritic cells and CD8+ T cells into the tumor tissue, activating antitumor immunity and hindering tumor progression [173]. This evidence concerns the gene IL1B and neoplasm.